The Crucial Role of the Therapeutic Window in Understanding the Clinical Relevance of the Poor Versus the Ultrarapid Metabolizer Phenotypes in Subjects Taking Drugs Metabolized by CYP2D6 or CYP2C19

This publication has 34 references indexed in Scilit:

• The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
  Breast Cancer Research and Treatment, 2006
• Heterozygous Mutation in CYP2C19 Significantly Increases the Concentration/Dose Ratio of Racemic Citalopram and Escitalopram (S-citalopram)
  Therapeutic Drug Monitoring, 2006
• Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines
  Expert Opinion on Pharmacotherapy, 2006
• Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19
  Psychosomatics, 2006
• A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
  Clinical Pharmacology & Therapeutics, 2006
• The Impact of Pharmacogenomics on Postoperative Nausea and Vomiting
  Anesthesiology, 2005
• Clinical Pharmacokinetics of Atomoxetine
  Clinical Pharmacokinetics, 2005
• Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
  The Pharmacogenomics Journal, 2004
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
  Molecular Psychiatry, 2004
• Adverse Drug Reactions to Oxycodone and Hydrocodone in CYP2D6 Ultrarapid Metabolizers
  Journal of Clinical Psychopharmacology, 2003